DUSA Pharmaceuticals, Inc.(R) Announces Third Quarter Financial Results and Corporate Highlights Conference Call
More News related to DUSA
- DUSA Pharma (DUSA) Encouraged By SCC Study to Explore Benefits of Levulan PDT
- Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period
- DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
- DUSA Pharma (DUSA) Posts Q3 Loss of 2c, Beats by 2c
- DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results
More News related to Press Releases
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
WILMINGTON, Mass., Nov. 3 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its corporate highlights and third quarter financial results press release will be issued on Friday, November 6 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Friday, November 6 - 8:30 a.m. E.T.
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA
For International callers use
502.498.8422
A recorded replay of the call will be available approximately 15 minutes
following the call
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site approximately six hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc.(® )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan( )PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(®). DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our web site at www.dusapharma.com.
SOURCE DUSA Pharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
